NCT00520390View on ClinicalTrials.gov

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2007

Conditions
LymphomaAdvanced Solid Tumors
Interventions
DRUG

EZN-2208

Trial Locations (1)

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY